All were NH eligible. 
oral meds; 50% Insulin. 44% had ADL score <1=6, 79% had SPMSQ score <1= 6 (MCI).
What is On Lok? First PACEmodel program located in San Francisco.
Controlled for: sex, race, age, type of meds, co-morbid conditions, year entered. 2) A1c is used to target glycemic control in patients wI OM.
3) No data available to show that A1c levels in older adults have an impact on fxnl decline or disability. 4) AGS recommends Alc <8% for frail elderly or those with limited life expectancy. VA recommends A1c<9%. ADA "Iess stringent" than <7% in frail elderly.
Study Measures: 1) A1c «7, 7 to 7.9, 8 to 8.9 & >1= 9) in quartiles.
2) ADl Scale (on each measure for bathing, dressing, eating, transferring or toileting a score of 2 is given for independent, 1 for partially dependent & 0 for completely dependent, total score ranging from 0 to 10). This was done initially (within 6 months before first A1c 2) At 6 months, no clear relationship between A1c & death/fxnl decline. At 12 months each higher level of Alc was assoc wi a lower rate of death/fxnl decline but it was not statistically significant (P for trend 0.24). By 24 months higher A1c was assoc with less fxnl decline or death wi a sig P value of 0.006.
3) Best outcomes: A1c 8-8.9%
STRENGTHS:
1) Simple study, controlled population, first study to look at fxnl outcomes related to DM2 management in a frail elderly population.
2) Changes the way we look at Alc as an indicator of DM2 control in this group.
WEAKN ESSES:
1) Observational study, confounding likely although they tried to control for several factors; others may have not been accounted for.
2) PACEparticipants are likely different from those not participating.
